18469-52-8

Basic information

• Product Name: Methyl 4-(aminomethyl)benzoate
• Synonyms: BUTTPARK 33\11-77;4-(AMINOMETHYL)BENZOIC ACID METHYL ESTER;4-(AMINOMETHYL)BENZOIC ACID METHYL ESTER HYDROCHLORIDE;4-METHOXYCARBONYL-BENZYLAMINE HYDROCHLORIDE;4-Aminomethylbenzoic acid methyl ester(HCl);Methyl 4-(aminomethyl)benzoate;Methyl 4-(aminomethyl);Benzoic acid, 4-(aminomethyl)-, methyl ester
• CAS NO: 18469-52-8
• Molecular Formula: C₉H₁₁NO₂
• Molecular Weight: 201.65
• Product Categories: Aromatic Esters;Aminomethyl's;Phenyls & Phenyl-Het;Phenyls & Phenyl-Het
• Mol File: 18469-52-8.mol
• Article Data: 56

Chemical Properties

• Melting Point: 243 °C (dec.)(lit.)
• Boiling Point: 278.699 °C at 760 mmHg
• Flash Point: 138.116 °C
• Appearance: /
• Density: 1.121 g/cm³
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• PKA: 8.67±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-(aminomethyl)benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-(aminomethyl)benzoate(18469-52-8)
• EPA Substance Registry System: Methyl 4-(aminomethyl)benzoate(18469-52-8)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 18469-52-8(Hazardous Substances Data)

Usage

General Description

Methyl 4-(aminomethyl)benzoate is an organic compound with the molecular formula C9H11NO2. It is often used in the synthesis of pharmaceuticals and is known for its wide range of biological activities. Methyl 4-(aminomethyl)benzoate has been found to exhibit antimicrobial, anti-inflammatory, and analgesic properties, making it a valuable compound in drug development. It is commonly used as a reagent in organic synthesis and as an intermediate in the production of various pharmaceuticals. The compound has also been studied for its potential in the treatment of various conditions, including cancer and neurodegenerative diseases. Overall, Methyl 4-(aminomethyl)benzoate is a versatile and important chemical in the field of medicinal chemistry.

InChI:InChI=1/C9H11NO2.ClH/c1-12-9(11)8-4-2-7(6-10)3-5-8;/h2-5H,6,10H2,1H3;1H

Upstream product

• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 1377451-52-9 2-({[4-(methoxycarbonyl)phenyl]methyl}carbamoyl)benzoic acid 
• 1126-46-1 Methyl 4-chlorobenzoate 
• 56-91-7 p-aminomethylbenzoic acid 
• 99-94-5 p-Toluic acid 
• 99-75-2 4-methyl-benzoic acid methyl ester 
• 586-76-5 4-Bromobenzoic acid 
• 619-42-1 4-methoxycarbonylphenyl bromide 
• 619-65-8 4-cyanobenzoic Acid 
• 1571-08-0 methyl 4-formylbenzoate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 6232-11-7 methyl 4-(aminomethyl)benzoate hydrochloride 
• 6757-31-9 methyl-4-carbamoylbenzoate 
• 7377-26-6 4-Methoxycarbonylbenzoyl chloride 

Downstream Products

• 133052-65-0 4-[(5-Fluoro-2-nitro-phenylamino)-methyl]-benzoic acid methyl ester 
• 120157-96-2 methyl 4-[N-(tert-butoxycarbonyl)aminomethyl]benzoate 
• 133052-67-2 methyl 4-N-(2-nitrophenyl)aminomethylbenzoate 
• 172036-06-5 4-[3-(4-{2-[(2-{[2-(Bis-methoxycarbonylmethyl-amino)-ethyl]-methoxycarbonylmethyl-amino}-ethyl)-methoxycarbonylmethyl-amino]-2-methoxycarbonyl-ethyl}-phenyl)-ureidomethyl]-benzoic acid methyl ester 
• 172036-05-4 4-[3-(4-{2-[(2-{[2-(Bis-methoxycarbonylmethyl-amino)-ethyl]-methoxycarbonylmethyl-amino}-ethyl)-methoxycarbonylmethyl-amino]-2-methoxycarbonyl-ethyl}-phenyl)-thioureidomethyl]-benzoic acid methyl ester 
• 180397-75-5 methyl (N)-4-(((4-(methoxycarbonyl)benzyl)imino)methyl)benzoate 
• 265311-88-4 4-{[(5-hydroxy-1H-indole-2-carbonyl)-amino]-methyl}-benzoic acid methyl ester 
• 1027381-69-6 4-[(2-propyl-pentanoylamino)-methyl]-benzoic acid methyl ester 
• 1021389-78-5 4-({[1-(4-difluoromethoxy-benzyl)-5-fluoro-1H-indazole-3-carbonyl]-amino}-methyl)-benzoic acid methyl ester 
• 858781-03-0 4-({[(R)-3-((2S,3S)-3-tert-Butoxycarbonylamino-2-hydroxy-4-phenyl-butyryl)-5,5-dimethyl-thiazolidine-4-carbonyl]-amino}-methyl)-benzoic acid methyl ester 
• 197844-00-1 4-[(3,5-Di-tert-butyl-benzylamino)-methyl]-benzoic acid methyl ester 
• 216966-20-0 {4-[(3,5-Di-tert-butyl-benzylamino)-methyl]-phenyl}-methanol 
• 216966-45-9 methyl 4-{[(anthracen-9-ylmethyl)amino]methyl}benzoate 
• 216966-47-1 (4-{[(anthracen-9-ylmethyl)amino]methyl}phenyl)methanol 

Relevant articles and documents

A novel harmine derivative, N-(4-(hydroxycarbamoyl)benzyl)-1-(4- methoxyphenyl)-9H-pyrido[3,4-b]indole-3-carboxamide (HBC), as histone deacetylase inhibitor: in vitro antiproliferation, apoptosis induction, cell cycle arrest, and antimetastatic effects

This study aims to design and synthesize a novel harmine derivative N-(4-(hydroxycarbamoyl) benzyl)-1-(4-methoxyphenyl)-9H-pyrido [3,4-b]indole-3-carboxamide (HBC) as histone deacetylase (HDAC) inhibitor, and evaluate its antitumor activities and anti-met

The development of a novel transforming growth factor-β (TGF-β) inhibitor that disrupts ligand-receptor interactions

Transforming growth factor-β (TGF-β) plays an important role in regulating epithelial to mesenchymal transition (EMT) and the TGF-β signaling pathway is a potential target for therapeutic intervention in the development of many diseases, such as fibrosis and cancer. Most currently available inhibitors of TGF-β signaling function as TGF-β receptor I (TβR-I) kinase inhibitors, however, such kinase inhibitors often lack specificity. In the present study, we targeted the extracellular protein binding domain of the TGF-β receptor II (TβR-II) to interfere with the protein-protein interactions (PPIs) between TGF-β and its receptors. One compound, CJJ300, inhibited TGF-β signaling by disrupting the formation of the TGF-β-TβR-I-TβR-II signaling complex. Treatment of A549 cells with CJJ300 resulted in the inhibition of downstream signaling events such as the phosphorylation of key factors along the TGF-β pathway and the induction of EMT markers. Concomitant with these effects, CJJ300 significantly inhibited cell migration. The present study describes for the first time a designed molecule that can regulate TGF-β-induced signaling and EMT by interfering with the PPIs required for the formation of the TGF-β signaling complex. Therefore, CJJ300 can be an important lead compound with which to study TGF-β signaling and to design more potent TGF-β signaling antagonists.

Nicotinamide Phosphoribosyltransferase (NAMPT) Is a New Target of Antitumor Agent Chidamide

Chidamide is a histone deacetylase (HDAC) inhibitor that is currently used to treat cutaneous T-cell lymphoma in clinic. Herein nicotinamide phosphoribosyltransferase (NAMPT) was identified to be a new target of chidamide on the basis of the pharmacophore analysis, molecular docking, biological assays, inhibitor design, and structure-activity relationship study. The polypharmacology of chidamide will provide important information for better understanding its antitumor mechanism. Also, design of dual NAMPT/HDAC inhibitors may serve as an effective strategy to develop novel antitumor agents.